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INTRODUCTION
The heart rate is usually increased in chronic heart failure and correlates positively with mortality (Lechat et al., 2001 ). The precise role of the heart rate in the pathophysiology of chronic heart failure is poorly understood, but heart rate reduction (HRR) is considered a specific therapeutic target in patients with heart failure (Laperche et al., 1999) . Indeed, HRR increases the duration of both left ventricular (LV) filling and diastolic coronary perfusion, which are altered in heart failure. HRR also reduces myocardial O 2 consumption. However, the effects of long-term HRR on chronic heart failure are largely unknown. In patients with heart failure and cardiac pacing, reversal of beta-blockers-induced bradycardia worsened ventricular function (Thackray et al. 2006) . Clinical trials of beta-blockers in chronic heart failure do not allow to conclude definitely regarding the intrinsic effect of the associated HRR (Lechat et al., 2001; Gullestad et al., 2005) . Indeed, beta-blockers have additional properties, including inhibition of catecholamine-induced myocardial toxicity and decreased renin secretion, and are likely to favorably influence cardiac remodeling.
The class of pure heart-rate-lowering agents --inhibitors of the cardiac pacemaker I f current --provides an opportunity to study the direct effects of HRR in heart failure.
Ivabradine is a selective I f -current inhibitor that induces HRR in a dose-dependent manner, with no direct hemodynamic effects (Simon et al., 1995; Vilaine et al., 2006) . In a rat model of myocardial infarction, ivabradine was beneficial by improving LV systolic function, reducing collagen density in the non-infarcted myocardium, and improving myocardial perfusion and the coronary reserve (Mulder et al., 2004; Dedkov et al., 2007) .
JPET #130237 6 cycle and stored for off-line analysis (PowerLab/16SP, AD Instruments). The mean heart rate was calculated and ventricular arrhythmias were identified and quantified manually.
Echocardiographic studies
Rats underwent echocardiography under isoflurane anaesthesia (1.0%-1.5% in oxygen), just before and then after 30 and 90 days of ivabradine treatment, using a Toshiba PowerVision 6000, SSA 370A apparatus equipped with a phase array 7.5-MHz transducer.
The left ventricle was imaged as previously described (Prunier et al., 2002; Chen et al., 2004) . ; cardiac output (SV × HR); and peak velocity of early diastolic mitral filling (E), E-wave deceleration time and isovolumic relaxation time. Peak velocities of systolic (Sa) and early diastolic (Ea) LV motion were measured by pulsed-wave TDI, with the sample volume placed at the lateral corner of the mitral annulus, to assess global LV function in the longitudinal axis. E/Ea was calculated to estimate LV end-diastolic pressure ({Prunier et al., 2002; Slama et al., 2005) . The strain rate of the LV posterolateral wall was derived from time-movement colour TDI and was measured in the parasternal short-axis view, as previously described (Chen et al., 2004) .
Hemodynamic measurements
The hemodynamic study was performed after the last echographic examination, just before euthanasia (after 90 days of treatment) as previously described (Prunier et al., 2002; Chen et al., 2004) . In brief, rats were sedated with ketamine (50 mg/g) and xylazine (10 mg/g) This article has not been copyedited and formatted. The final version may differ from this version. 
Cardiac morphometry and molecular remodeling
Before and after the hemodynamic measurements, the rats were carefully inspected for pleural and abdominal effusion. Then, blood was removed by aortic puncture, and organs were immediately rinsed by infusion with cold saline. The lungs, atria and right and left ventricles were dissected and weighed. Then, cross-sections of the LV were made at the level of the papillary muscles, frozen in liquid nitrogen and stored at -80°C for analysis.
Cardiac fibrosis was assessed by semi-quantitative measurement of cardiac collagen density. Eight-µm-thick LV cryosections were stained with Sirius red and analysed microscopically (x500) by a trained operator blinded to the treatment arm. Fibrosis was scored from 0 to 9 as follows: 0-3 for expansion across the whole LV section, 0-3 for transmural expansion, 0 or 1 for myocytes necrosis, and 0 or 1 for perivascular fibrosis.
Frozen LV tissue samples were homogenized in ice-cold buffer, and total creatinine kinase, cytochrome c oxidase and citrate synthase activities were assayed after extraction, by using coupled enzyme systems as previously described (De Sousa et al., 1999) . Other samples were used for mRNA quantification of type 2a sarco-endoplasmic reticulum Ca 
Statistical analysis
Continuous data are expressed as means ± SEM and categorical data as percentages.
Comparison of means among groups was based on ANOVA and the Newman-Keuls test.
Group-to-group comparisons were done using the Bonferroni correction. Linear regression analysis was based on the least-squares method. P<0.05 was considered to denote a significant difference.
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Results
Level of ivabradine-induced HRR
Twelve-hour ECG monitoring revealed a 19% HRR in rats with aortic banding treated with ivabradine as compared with untreated rats (277±20 vs 345±26 beats/min, p<0.005), throughout the 12-hour recording period (Fig. 1) . A similar 19% HRR in ivabradine-treated as compared with untreated rats was observed during echography ( Table 1) .
Effect of aortic banding and HRR on LV hypertrophy
Echographic examination revealed a marked LV hypertrophy as early as 14 days after aortic banding (i.e. before ivabradine treatment) in the two banded groups (Figure 2 ). At sacrifice, LV hypertrophy in the untreated group averaged 55% (Table 2) .
Ivabradine treatment was associated with more marked LV hypertrophy (70%, +10%
vs untreated rats, p<0.05), but not with an increase in LV diastolic diameter (11.5±0.1 vs 11.1±0.2 mm, p=0.09, Table 1 ).
Effect of aortic banding and HRR on LV systolic function
Aortic banding was associated with a gradual decrease in LV stroke volume, LV shortening fraction, and cardiac output that averaged respectively 41%, 34% and 38% at 3 months ( Fig. 2 ). TDI parameters (Sa peak velocity and systolic peak strain rate) were also reduced, whereas dP/dt max was unchanged (Table 1) . HRR was associated with a 19% increase in stroke volume (p<0.01) but no change in cardiac output or in other parameters of LV systolic function. As HRR was associated with a proportional increase in the ejection time, the stroke volume/ejection time ratio did not change.
Effect of aortic banding and HRR on LV diastolic function and filling pressure
Aortic banding was associated with a gradual alteration of LV filling, as shown by an increased E/Ea at echo and by hemodynamic data at 3 months, characterized by a marked increase in LV filling pressure (Fig. 2 , Table 1 ). The increased E/Ea and almost unchanged LV end-diastolic volume suggested a decrease in LV compliance in banded rats compared to sham-operated controls.
In ivabradine-treated rats, LV filling pressure increased further, as shown by increased E/Ea and LVEDP values as compared with untreated rats. Increased atrial weight, lung weight and RV weight in rats treated with ivabradine for 3 months (38%, 30% and 54%, respectively vs untreated rats, p<0.01) were consistent with increased LV filling pressure This was further supported by the increased prevalence of pleural or peritoneal effusion in these rats (36 vs 19%, p<0.05, Table 2 ).
Effect of aortic banding and HRR on tissue and molecular LV remodeling
Marked LV perivascular and subendocardial fibrosis was seen in banded rats at 3 months. This fibrosis further increased in ivabradine-treated rats (fibrosis score: 6.4±0.3 vs 5.2±0.2 in treated and untreated rats, respectively, p < 0.05) and was essentially located in the subendocardium (Fig. 3) .
The ANP mRNA level increased markedly in the LV of banded rats as compared to sham-operated rats (Table 3) . A further increase was observed in ivabradine-treated rats (6.4±0.3 vs 5.2±0.2 a.u. in treated and untreated rats, respectively, p<0.05). A non-significant increase in SERCA2a mRNA levels was found in banded rats compared to sham-operated rats. In contrast, SERCA2a mRNA levels decreased in ivabradine-treated rats as compared to untreated banded rats (1.05±0.09 vs 1.42±0.13, p<0.05). Citrate synthase and cytochrome oxidase activities did not differ in the three rat groups. In contrast, creatine kinase activity fell in the two banded groups as compared to sham-operated controls (p<0.05 for the two comparisons), with no difference between ivabradine-treated and untreated rats.
Discussion
This study demonstrates that pressure overload-induced heart failure in rats is not improved by chronic HRR. This model has been thoroughly characterized in a number of previous studies. After banding of the ascending aorta, the pressure overload of the left ventricle increases gradually during rat growth, resulting in progressive LV hypertrophy, LV fibrosis and congestive heart failure (Feldman et al., 1993; Litwin et al., 1995) . A number of studies have shown beneficial effects of angiotensin-converting-enzyme inhibitors, betablockers and statins in aortic banding-induced heart failure (Weinberg et al., 1994; Kagaya et al., 1996; Marano et al., 2002; Pape et al., 2002; Grimm et al., 2001; Indolfi et al., 2002) .
Several reasons led us to postulate that HRR itself could also be beneficial. First, hypertrophy impairs relaxation, which shortens the duration of LV filling (Leite-Moreira et al., 1999) .
Accordingly, we postulated that HRR would improve LV filling. In addition, ivabradinemediated HRR has no negative lusitropic effect and further increases the LV filling duration as compared to beta-blockers (Colin et al., 2002) . Second, as the force-frequency relationship is altered in heart failure (Mulieri et al., 1992), we suspected that HRR might allow the heart to operate on the ascending limb of this relation. Third, myocardial perfusion, which is altered in hypertrophied ventricles (Hittinger et al., 1995) , occurs mainly during diastole.
Accordingly, we postulated that HRR, by extending the diastole, would improve myocardial perfusion and, thus, myocardial metabolism. In addition, angiogenic effects as well as an increase in coronary reserve were demonstrated using alinidine-mediated HRR (Lei et al, 2004) . Finally, because the heart rate is a major determinant of myocardial O 2 consumption (Colin et al., 2003) , we thought that HRR could be beneficial in heart failure, as in coronary artery disease (Shinke et al, 1999; Borer et al., 2003 ).
In our model, chronic HRR increased LV filling pressure, as demonstrated by echographic and hemodynamic findings and by a marked increase in atrium and lung weight.
This article has not been copyedited and formatted. The final version may differ from this version. An HRR-induced worsening of LV diastolic dysfunction was suggested by a markedly increased LVEDP, with no significant increase in LV end-diastolic volume. Such an effect might be explained as follows. First, HRR per se increased LV filling but aortic banding physically precluded any resulting increase in LV stroke volume and therefore led to a major rise in LVEDP because of the poor LV compliance characteristic of pressure-overloadinduced LVH. Second, elevated LVEDP further increased LV hypertrophy and fibrosis, which further reduced LV compliance. In this type of maladaptive LV hypertrophy, the main mechanism leading to LV hypertrophy and fibrosis is considered to be the increase in wall stress, although neuro-humoral alterations are likely also to play a role (Mercadier et al., 2007) . Regarding LV systolic wall stress, we could not directly measure the systolic pressure gradient through the aortic clip. However, the mean pressure gradient would likely have been little altered by HRR, as the stroke volume/ejection time ratio did not change (Dangas et al., 1997) . The HRR-related increase in LV ejection duration clearly increased the duration of systolic LV wall stress, a phenomenon that might worsen LV hypertrophy. LV diastolic wall stress also was most likely increased by HHR, because of the marked increase in both LV filling pressure and filling duration, associated with a slight increase in LV volume. In addition, hypertrophy, as well as high diastolic and systolic LV wall stress, favours myocardial ischemia and subsequent fibrosis, especially in the subendocardium (Hittinger et al., 1989) .
To determine whether the HRR-associated structural and functional changes observed were reversible, we withdrew ivabradine treatment in 8 rats. Three days after treatment cessation the heart rate returned to the values observed in untreated rats, while LV diastolic diameter fell and a major decrease in E/Ea occurred, indicating a marked decrease in LV filling pressure. These results, which are consistent with a downward shift of the operating point along the same diastolic pressure-volume relationship, strongly suggest that HRR was This article has not been copyedited and formatted. The final version may differ from this version. Regarding LV systolic function, pressure overload resulted in a depressed LV ejection fraction, which is related more to afterload mismatch than to decreased LV contractility (Ross et al., 1976) . Indeed, LV fractional shortening was markedly decreased while LV dP/dt max , which is less load-dependent than the ejectional parameter, was unchanged. Importantly, HRR was not associated with significant changes in isovolumic or ejectional parameters of LV systolic function, in keeping with ivabradine's lack of a negative inotropic effect. At the subcellular level, however, HRR was associated with increased ANP mRNA and decreased SERCA2a mRNA levels as compared with untreated rats, and this latter decrease has been shown to correlate with the transition to cardiac failure in this model (Feldman et al., 1993) .
As previously reported (De Sousa et al., 1999) , aortic banding resulted in decreased activity of creatine kinase, an enzyme involved in energy transfer within cardiac myocytes. No further decrease in this activity was observed in ivabradine-treated rats, at a time when both LV hypertrophy and dysfunction were more severe than in untreated rats, indicating some degree of preservation of energy metabolism by HRR.
Previous studies have shown beneficial effects of If current inhibitors in the myocardial infarction-induced heart failure model. Mulder et al. (Mulder et al., 2004) demonstrated that a 16% ivabradine-mediated HRR maintained for 90 days increased the LV shortening fraction without LV dilation, and that this effect persisted after treatment cessation.
Using isolated Langendorff-perfused hearts, authors also observed a leftward shift of the developed pressure-volume relationship in ivabradine-treated rats as compared with controls. Moreover, impaired sinus node function and arrhythmogenic ion-channel remodelling during heart failure needs also to be taken into account (Nattel et al., 2007) .
Our study has some limitations. Our measurement of LVEDP in vivo clearly yielded underestimated values due to the direct LV puncture in open-chest rats. LVEDP indirect assessment using Doppler E/Ea probably better reflected actual pressures. Because we tested only one dosage of ivabradine, the effects of other dosages are unknown. Similarly, we cannot directly extrapolate the results of our study to situations in which ivabradine treatment starts later after aortic banding.
In summary, long-term HRR showed no beneficial effects in pressure overloadinduced LV hypertrophy in the rat. On the contrary, it favoured LV hypertrophy, fibrosis, Table 4 : Echographic values before and 3 days after cessation of 3 months of treatment with ivabradine, 10 mg/kg/d, in 8 rats. * p<0.05 and ** p<0.01, vs treatment.
On treatment 3 days after treatment cessation
Heart rate (beats/min) 283 ± 14 315 ± 7 ** LVEDV (mm) 11.8 ± 0.4 11.6 ± 0.4 * LV shortening fraction (%) 33 ± 4 33 ± 6
Stroke volume (µL) 516 ± 14 490 ± 18 * Cardiac output (ml/min) 144 ± 7 155 ± 5 E/Ea ratio 32 ± 2 23 ± 2 * This article has not been copyedited and formatted. The final version may differ from this version. 
